Why Is French Pharma Giant Sanofi Stock Trading Higher On Thursday?
1. FDA grants orphan drug status to SNY's rilzabrutinib for rare diseases. 2. Rilzabrutinib shows promising results for wAIHA and IgG4-RD patients. 3. FDA decision on ITP expected by August 29, boosting regulatory outlook. 4. Sanofi's stock rose 3.54% following the news on rilzabrutinib. 5. Qfitlia also approved for hemophilia, indicating strong pipeline performance.